156.51M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

Similar securities

Based on sector and market capitalization

Report issue